US 11,897,876 B2
Isoxazolidines as RIPK1 inhibitors and use thereof
Elisabeth Defossa, Frankfurt am Main (DE); Uwe Heinelt, Frankfurt am Main (DE); Hans Matter, Frankfurt am Main (DE); Maria Mendez-Perez, Frankfurt am Main (DE); Nils Rackelmann, Frankfurt am Main (DE); Kurt Ritter, Frankfurt am Main (DE); Hauke Szillat, Frankfurt am Main (DE); and Gernot Zech, Frankfurt am Main (DE)
Assigned to GENZYME CORPORATION, Cambridge, MA (US)
Filed by GENZYME CORPORATION, Cambridge, MA (US)
Filed on Nov. 9, 2022, as Appl. No. 17/983,883.
Prior Publication US 2023/0203027 A1, Jun. 29, 2023
Int. Cl. C07D 417/14 (2006.01)
CPC C07D 417/14 (2013.01) 27 Claims
 
1. A compound of formula I:

OG Complex Work Unit Chemistry
wherein
A represents a five-membered heteroaryl group in which 2 or 3 ring atoms are independently selected from nitrogen, which is optionally substituted by R3 and R4;
R1 represents H or CH3,
R2 represents Cl, F or CN,
R3 represents H or CH3,
R4 represents H, CH3 or cyclopropyl,
R5 represents H or F;
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.